Abstract 575
Background
People with dementia have poorer cancer outcomes than those without. Little information exists concerning implications of comorbid cancer-dementia for people having cancer treatment in an ambulatory care setting. The purpose of this focused ethnography is to characterise the environment, behaviour and processes that comprise the setting, and to explore what constitutes ‘good care’ in this context.
Trial design
The aim of this focused ethnography is to establish an empirically-based conceptual foundation to inform development of innovations to improve the way treatment and support is offered to people with dementia having cancer treatment. Objectives include: Understanding the physical fabric of the ambulatory care environment, and how this shapes patterns of behaviour and processes; Understanding the actions of those involved in the receipt or provision of care for people with dementia having cancer treatment, through exploration of interactions, perceptions, and language. Understanding the processes involved in care delivery, and how these shape treatment and support offered to patients. Identify characteristics that constitute ‘good care’ and gain an understanding of barriers and facilitators. Identify which aspects of the ambulatory care setting are amenable to modification to meet the needs of this complex population. This project will allow formation of a rich picture of the cultural context in which behaviour, environment and processes are situated, and identify ways in which the organisation of care might be structured to provide a person-centred service for people with dementia. Participants: Participation will be invited from people with dementia having cancer treatment (n ≤ 10), informal carers (n ≤ 10), and staff members (oncologists, nurses, radiographers, support workers, administrative staff, and allied health professionals) (n ≤ 30). Methods: Data will be collected via observations, interviews and document analysis. Data will be analysed using constant comparison, informed by the analytic tradition of grounded theory (Glaser & Strauss 1967), to allow the researchers to establish an empirically-based conceptual and theoretical foundation that is grounded in the original data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Naomi Farrington.
Funding
National Institute for Health Research, United Kingdom.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract